Fierce Pharma

MAY 8, 2024

Following the lead of French pharmaceutical giant Sanofi, Pfizer has agreed to settle more than 10,000 personal-injury claims from users of heartburn drug Zantac, resolving litigation in several U. | Following the lead of French pharmaceutical giant Sanofi, Pfizer has agreed to settle more than 10,000 personal-injury claims from users of heartburn drug Zantac, resolving litigation in several U.S. state courts, according to Bloomberg.

Leads 359

Leads Pharmaceutical 359

MedCity News

MAY 8, 2024

Otsuka Pharmaceutical is launching a subsidiary that will commercialize its digital therapeutic Rejoyn — as well as other digital therapeutics and connected health products down the line. Last month, Rejoyn became the first FDA-cleared digital therapeutic for patients with depression. The post Otsuka Launches New Company to Commercialize Rejoyn, the First Digital Therapeutic for Depression appeared first on MedCity News.

FDA 134

FDA Pharmaceutical Patients Biopharma 134

Fierce Pharma

MAY 8, 2024

Once hailed as a landmark accomplishment for the speed with which it was developed and a shining example of British innovation, the AstraZeneca coronavirus vaccine has been grounded by the European | Once hailed as a landmark accomplishment and a shining example of British innovation, the AstraZeneca coronavirus vaccine has been grounded by the European Medicines Agency (EMA).

Marketing 350

Marketing Medicine 350

Clarivate

MAY 8, 2024

Discover how the Web of Science Research Intelligence platform will revolutionize research evaluation by driving responsible innovation and demonstrating societal impact. At Clarivate , we recognize the pivotal role that research plays in shaping the future. That’s why we’re excited to announce the development of Web of Science Research Intelligence , a next-generation software solution powered by AI that will empower researchers to accelerate breakthroughs and research institutions to better me

Competition 131

Competition Management Prospecting Networking 131

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

MAY 8, 2024

After Orchard Therapeutics’ gene therapy for a rare genetic disease was approved in March, Peter Marks, M.D., Ph.D., received a simple email from Commissioner Robert Califf, M.D. | After Orchard Therapeutics’ gene therapy for a rare genetic disease was approved in March, Peter Marks, M.D., Ph.D., received a simple email from Commissioner Robert Califf, M.D.

FDA 328

FDA 328

pharmaphorum

MAY 8, 2024

Regeneron’s gene therapy for otoferlin-related hearing loss restored hearing to normal levels in one profoundly deaf child within just 24 weeks

122

122

European Pharmaceutical Review

MAY 8, 2024

New data from a Phase IIa trial in moderate-to-severe atopic dermatitis has demonstrated that a novel monoclonal antibody (mAb) could facilitate dosing every 12 weeks for induction therapy. This is due to a 31-day half-life at anticipated therapeutic dose levels, Inmagene Biopharmaceuticals confirmed. Humanised anti-OX40 IgG1 mAb IMG-007 works via a silenced antibody -dependent cellular cytotoxicity (ADCC) function, Inmagene explained.

Safety 122

Safety Patients Medicine Medical 122

Fierce Pharma

MAY 8, 2024

After bringing slow-release schizophrenia drug Uzedy to market last year, Teva and France’s MedinCell are using the same playbook for a similar candidate. | The companies second go at a long-acting schizophrenia med uses popular antipsychotic olanzapine, which Eli Lilly first marketed in the 90s but found safety issues with its own long-acting version.

Safety 295

Safety Marketing 295

pharmaphorum

MAY 8, 2024

The first commercial sales of Spectral AI's DeepView wound imaging system for burns are due to start in the UK, its first market, later this year

Sales 122

Sales Marketing 122

Fierce Pharma

MAY 8, 2024

As U.S. drug shortages run rampant, lawmakers are getting creative with their attempts to ease the situation. | Under the framework, hospitals, purchasers and generic drugmakers could earn incentive payments after meeting new contracting and purchasing standards. The lawmakers proposed supply contracts with longer timelines, greater supply commitments and contingency deals with alternative manufacturers.

Manufacturing 287

Manufacturing 287

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Pharmaceutical Technology

MAY 8, 2024

AstraZeneca has begun the global withdrawal of its Covid-19 vaccine Vaxzevria, citing a surplus of updated vaccines.

119

119

Fierce Pharma

MAY 8, 2024

As the pharmaceutical and biopharma sector increasingly focuses on value-based pricing, sustained profitability and expanding market access, the need to leverage products as they mature has intensi | Understanding how to energize, extend and capitalize the lifespan of mature drugs

Biopharma 246

Biopharma Pharmaceutical Marketing 246

MedCity News

MAY 8, 2024

Transcarent recently announced that it raised $126 million in Series D funding led by General Catalyst and 7wireVentures. When asked what his exit strategy is, CEO Glen Tullman said he does not want to sell Transcarent, but sees an initial public offering as an option. The post Glen Tullman Has ‘No Interest’ In Selling Transcarent, But IPO Is a Possibility appeared first on MedCity News.

119

119

Fierce Pharma

MAY 8, 2024

In about a year after launching a revamp strategy under CEO Richard Francis, Teva has managed to return its generics business to growth, secure approvals for a pair of high-profile biosimilars | While CEO Richard Francis caveated that Teva still has a “long way to go,” he figures the company has shown it can execute on its "Pivot to Growth" transformation strategy “very well,” and is “consistently doing so quarter on quarter.

Management 243

Management 243

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

PharmaTech

MAY 8, 2024

The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.

118

118

Fierce Pharma

MAY 8, 2024

Apellis’ geographic atrophy drug Syfovre delivered what CEO Cedric Francois called “robust” growth in the first quarter, as its sales topped analysts’ expectations. | Apellis’ geographic atrophy drug Syfovre delivered what CEO Cedric Francois called “robust” growth in the first quarter, as its sales topped analysts’ expectations. But investors still dragged the company’s shares down by 10% on Tuesday.

Sales 162

Sales 162

MedCity News

MAY 8, 2024

Balancing the promise of personalized medicine with proper payment accuracy The post Navigating the Complexities of Payment for Genetic Testing appeared first on MedCity News.

Medicine 111

Medicine 111

pharmaphorum

MAY 8, 2024

Selective serotonin reuptake inhibitors (SSRIs) are the first-line drug therapy of choice for most people suffering from depression but often fail to work effectively. Now, a study suggests simple blood test could help predict those who will benefit.

110

110

Advertisement

PharmaTimes

MAY 8, 2024

Gossamer’s seralutinib is designed to treat pulmonary arterial hypertension and other indications

107

107

Pharmaceutical Technology

MAY 8, 2024

Coinfections can complicate disease management and hence continued surveillance and targeted intervention strategies are needed.

Management 105

Management 105

Pharmaceutical Commerce

MAY 8, 2024

The latest news for pharma industry insiders.

Pharma 105

Pharma 105

pharmaphorum

MAY 8, 2024

FDA advisors will meet on 10th June to discuss Eli Lilly's Alzheimer's candidate donanemab, shortly after casting an eye over Lykos' MDMA-based psychedelic for PTSD.

FDA 104

FDA 104

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

European Pharmaceutical Review

MAY 8, 2024

Although we have yet to understand the human microbiome and its role in disease fully, the scientific evidence on the efficacy of complex live biotherapeutic products (LBPs) in modulating the microbiome is striking, as evidenced by the approval of the first two commercial donor-derived products, Rebyota and VOWST, in 2022 and 2023, respectively. What are the top three trends in microbiome-based therapeutic development?

Manufacturing 98

Manufacturing Safety FDA Patients 98

pharmaphorum

MAY 8, 2024

Our round-up of biotech financings is headed by a $200m round for Zenas, with Cellectis, Reunion, Karius, Context, and Enlaza also raising nine-figure sums

103

103

European Pharmaceutical Review

MAY 8, 2024

US researchers have reported successful complete biosynthesis of the molecule QS-21, which is the active ingredient of soap bark, in engineered yeast. This method enable QS-21 to be a more cost-effective and environmentally sustainable option as an adjuvant in vaccines, they explained. [The yeast-based method] enables a more cost-effective and environmentally sustainable option as an adjuvant in vaccines” Derived from the Chilean soapbark tree (Quillaja saponaria), over the past 25 years,

Engineering 98

Engineering Leads Pharmaceutical 98

PharmaVoice

MAY 8, 2024

Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S. oncology.

Patients 98

Patients 98

Advertisement

Distribution

PharmaTimes

MAY 8, 2024

The findings could potentially lead to new therapies and could stop the growth of cancers

Leads 95

Leads Medicine 95

Clarivate

MAY 8, 2024

A glance at the 2023 and early 2024 life science dealmaking environment shows fewer, but higher-value, transactions. Life science companies are demonstrating their willingness to splash out to build portfolio depth in key areas but remain selective about their partnership decisions in the wake of uncertainty around the impending patent cliff, globally high interest rates, geopolitical tensions and the medication pricing impact of the recently enacted Inflation Reduction Act (IRA) in the U.S.

Pharma 59

Pharma Biopharma Prospecting Competition 59

PharmaTech

MAY 8, 2024

This study reviews changes in in-country testing (registration testing, import testing) requirements and analyzes current trends. In the context of international harmonization of good practices and standards as well as the improved information exchange between national regulatory authorities, in-country testing is considered outdated and redundant in many cases.

Pharmaceutical products 59

Pharmaceutical products Pharmaceutical 59

Pharmaceutical Technology

MAY 8, 2024

We look at the top six most important trends in pharmaceutical milling and how they are shaping the industry.

Pharmaceutical 59

Pharmaceutical 59

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales